A5047822288- Hepatitis C virus research
- Hepatitis B Virus Studies
- HIV/AIDS drug development and treatment
- Liver Disease Diagnosis and Treatment
- Respiratory viral infections research
- Systemic Lupus Erythematosus Research
- Cytomegalovirus and herpesvirus research
- Hemoglobinopathies and Related Disorders
- Chronic Lymphocytic Leukemia Research
- Iron Metabolism and Disorders
- Platelet Disorders and Treatments
- Neurological Complications and Syndromes
- Toxoplasma gondii Research Studies
- Neonatal Health and Biochemistry
- Forensic Anthropology and Bioarchaeology Studies
- Viral Infections and Outbreaks Research
- Bacterial Infections and Vaccines
- Parvovirus B19 Infection Studies
- Influenza Virus Research Studies
- Neonatal Respiratory Health Research
- Hypothalamic control of reproductive hormones
- Dermatoglyphics and Human Traits
- IL-33, ST2, and ILC Pathways
- Health Education and Validation
- Educational Practices and Challenges
AbbVie (United States)
2014-2024
American Evaluation Association
2023
Association of American Colleges and Universities
2023
Association of Colleges
2023
California State University System
2023
Teesside University
2014-2022
Children's National
2021
University of Michigan
2021
Korle Bu Teaching Hospital
2021
University of Ghana
2021
Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated interferon-free combination protease inhibitor ABT-450 ritonavir (ABT-450/r), NS5A ombitasvir (ABT-267), nonnucleoside polymerase dasabuvir (ABT-333), and ribavirin an open-label phase 3 trial involving previously untreated treated adults HCV genotype 1 compensated cirrhosis.We randomly assigned 380 Child-Pugh...
Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C (HCV) are at high risk for liver disease progression. However, interferon-based treatments HCV infection have significant toxicities, limiting treatment uptake.To assess the all-oral 3 direct-acting antiviral (3D) regimen of ombitasvir, paritaprevir (co-dosed ritonavir [paritaprevir/r]), dasabuvir, ribavirin in genotype 1-infected adults HIV-1 co-infection, including patients cirrhosis.TURQUOISE-I is a randomized,...
ABSTRACT Ombitasvir (ABT-267) is a hepatitis C virus (HCV) NS5A inhibitor with picomolar potency, pan-genotypic activity, and 50% effective concentrations (EC 50 s) of 0.82 to 19.3 pM against HCV genotypes 1 5 366 genotype 6a. retained these levels potency panel 69 6 chimeric replicons containing the gene derived from HCV-infected patients, despite existence natural sequence diversity within NS5A. In vitro resistance selection identified variants that conferred ombitasvir in at amino acid...
We describe here N-phenylpyrrolidine-based inhibitors of HCV NS5A with excellent potency, metabolic stability, and pharmacokinetics. Compounds 2S,5S stereochemistry at the pyrrolidine ring provided improved genotype 1 (GT1) potency compared to 2R,5R analogues. Furthermore, attachment substituents 4-position central N-phenyl group resulted in compounds potency. Substitution tert-butyl, as compound 38 (ABT-267), low-picomolar EC50 values superior It was discovered that a pan-genotypic...
Anticardiolipin antibodies (aCL) are induced both in the Antiphospholipid Syndrome (APS) and syphilis, but thrombosis, thrombocytopenia, pregnancy loss occur only APS. Differences specificity function of aCL might explain clinical differences between APS syphilis. This study compared effects on platelet activation aggregation affinity purified IgG anticardiolipin from 6 patients with (IgG-APS) 5 syphilis (IgG-syph). Platelet was studied by aggregometry flow cytometry. In presence low...
Telaprevir plus pegylated interferon/ribavirin (TPV+PegIFN/RBV) remains a therapeutic option for chronic hepatitis C virus (HCV) genotype (GT) 1 infection in many regions. We conducted two open-label, phase IIIb trials comparing safety and efficacy of all-oral ombitasvir/paritaprevir/ritonavir dasabuvir±ribavirin (OBV/PTV/r+DSV±RBV) TPV+PegIFN/RBV.Treatment-naïve (MALACHITE-I) or PegIFN/RBV-experienced (MALACHITE-II) non-cirrhotic, HCV GT1-infected patients were randomized to...
ABT-493 is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor, and ABT-530 an HCV NS5A inhibitor. These direct-acting antivirals (DAAs) demonstrated potent antiviral activity against major genotypes high barriers to resistance in vitro. In this open-label dose-ranging trial, safety were assessed during 3 days of monotherapy with or treatment-naive adults genotype 1 infection, without compensated cirrhosis. The presence baseline resistance-associated variants (RAVs)...
Annual influenza vaccination is routinely recommended for pediatric solid organ transplant recipients. However, there are limited data defining the immune response to inactivated vaccine in this population.
This single center, retrospective study describes experience with a hybrid prevention strategy combining short-course antiviral prophylaxis and preemptive cytomegalovirus (CMV) polymerase chain reaction (PCR) monitoring.One hundred twenty-two pediatric liver transplantation recipients were followed up for median of 2.3 years posttransplantation. Subjects received minimum 14 days postoperative ganciclovir, by monthly CMV PCR monitoring.Forty-three seronegative seropositive grafts considered...
To examine the safety and efficacy of ombitasvir ABT-450 with ritonavir (ABT-450/r) ± ribavirin (RBV) in treatment-naïve, non-cirrhotic adults chronic HCV genotype 1-3 infection.Patients this open-label, exploratory, phase 2, multicenter study received (25 mg QD) ABT-450/r (200/100 RBV for 12 weeks. Primary endpoint was RNA < lower limit quantitation (LLOQ) from week 4 through 12. Sustained virologic response weeks post-treatment (SVR12) a secondary endpoint.Sixty-one patients were enrolled....
A unique anti-interleukin (IL)-13 monoclonal antibody, RPC4046, was generated on the basis of differential IL-13 receptor (R) blockade as assessed in a murine asthma model; safety, tolerability, pharmacokinetics, and pharmacodynamics RPC4046 were evaluated first-in-human study.Anti-IL-13 antibodies with varying blocking specificity ovalbumin-induced model. randomized, double-blind, placebo-controlled, dose-escalation study (NCT00986037) conducted healthy adults patients mild to moderate...
This first-in-human dose-ascending study investigated pharmacokinetics, safety, and tolerability of pibrentasvir following single multiple doses in healthy volunteers. Additionally, the effects food ritonavir on were assessed a crossover design. The starting dose was selected based no-observed-adverse-effect-level exposure from preclinical studies. Dose escalations subsequent cohorts dependent reviews tolerability, pharmacokinetic data previous cohorts. Pibrentasvir exposures increased...
To describe the relative contribution of and risk factors for both community-acquired nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infections.Retrospective cohort study.270-bed, tertiary-care children's hospital.All MRSA-infected children from whom MRSA was recovered between October 1, 1999, September 30, 2001.Demographic, clinical, factor data were abstracted medical records. Categorical variables analyzed using chi-square or Fisher's exact test continuous Mann-Whitney...
Abstract Glecaprevir and pibrentasvir are direct‐acting antiviral agents being developed as combination therapy for the treatment of chronic hepatitis C virus infection. The aim present studies was to assess effect race ethnicity (white, Han Chinese, Japanese) on pharmacokinetics safety multiple oral doses glecaprevir given alone in combination. Two multiple‐dose, single‐center, phase 1 were conducted healthy adult male female subjects (n = 170) respective Asian white race/ethnicity. (100,...
Abstract Healthy plant‐based diets (hPBD) are being promoted to reduce the risks of cardiovascular and associated diseases. This study investigates short‐term adherence a hPBD examine whether these dietary changes impact weight risk factors. A simple, uncontrolled, before after design was used. Twenty women (mean BMI 31 ± 4 kg/m 2 ) participated in 6‐week intervention. Participants completed 3‐week reset, eliminating all refined sugar, heavily processed foods, artificial sweeteners, alcohol,...
La determinación de sexo en restos esqueletales es uno los pilares fundamentales al construir el perfil biológico un individuo.Los métodos que incluyen la cintura pélvica han demostrado ser más precisos; sin embargo, no son siempre aplicables y su reemplazo métricos otros elementos del esqueleto una alternativa.Múltiples estudios específicos a población analizada afectados por cambios seculares.Se investigó dimorfismo sexual escápula, clavícula, húmero, radio, ulna, fémur, tibia fíbula,...
Severe hypothyroidism can cause a distinct form of precocious puberty in children, characterized by delayed skeletal maturation, predominance FSH-mediated effects over LH-mediated function, and reversal sexual precocity upon thyroid hormone replacement. The etiology this unusual children remains poorly understood. Recently, three mutations the FSH receptor gene have been identified women with spontaneous ovarian hyperstimulation during pregnancy. All mutated receptors displayed abnormally...